This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

shouldnt worry gf I think the news is filtering through.... check your stockwatch

rob.......

I don't think it's going to happen today.

MS

I would send one as well but i`m not sure they would get mine at the moment.Bloody computer is playing up.Goldfinger i have posted an apology on the Vane thread for not getting back in contact with you.
db66

Mickey.......... if it is notifiable its gotta happen today!!!!!!

Heres the auto reply I got back, I cant get clare on the phone so ive left an e-mail..............................

I am currently out of the office until Monday 21st March. If the matter is urgent you can contact my assistant, Clare Graves on: 01223 477677 or Clare.Graves@mmigroup.co.uk

cheers GF.

It's got to be good news, look at the sp.

MS

Certainly looks like some have had a whiff of good news probably clients of the house broker.

cheers GF.

I agree, to many buys coming in now for it to be bad news surely.
DB66

I do not know wether to be more pleased with mmg or Cobra bio today, would be Cobra but my mmg holding is considerably greater
Have a great weekend guy's and roll on Monday

Bottle up and go son...............

See ya later tonight guys, hopefully we will have the news.

cheers GF.

Anything in this weekends papers???????????.

cheers GF.

No need to worry gf There is news coming soon..keep buying.

Come on MItzy, spill the beans.

cheers GF.

Hopefully an annoucement from MMG on the latest news from Genvax following the presentation last Friday...200p is the resistance but should break when the news is out.

Doing pretty well again this morning, more or less samr pattern as Friday, up and down like a yo yo.

cheers GF.

Vaccine hopes for blood cancers

Scientists are looking at treating many types of cancer with vaccines
A vaccine to help patients fend off blood cancers could be a reality in the near future.
It could even be given to healthy people who donate bone marrow to treat patients with multiple myeloma.

Scientists have been testing candidate jabs in humans and say early results are promising.

These use specially-treated material from the patient's cancer to try to encourage the body's own immune system to pick out and attack myeloma cells.

Cancer vaccine

Myeloma develops from cells within the bone marrow called plasma cells, which produce proteins called antibodies to help to fight infection.

It does not give you cancer. There is no risk to the donor.

Researcher Dr Michael Bishop

In myeloma, a single plasma cell develops faults and multiplies out of control, producing excessive amounts of a single type of antibody.

It affects approximately 3,500 people in the UK each year, and is notoriously difficult to treat.

Even with chemotherapy and a bone marrow transplant, the average patient will live for only two to four years, meaning new treatments are urgently needed.

For the last four years, researchers from the National Cancer Institute in the US have been testing a trial vaccine in myeloma patients and healthy people donating bone marrow to these patients.

Attack

Researcher Dr Michael Bishop from the NCI's campus in Bethesda, Maryland, said: "With conventional bone marrow transplants you are transferring a new, healthy immune system to the patients with myeloma, and this new immune system is capable of recognising myeloma and attacking it.

"But this can be a relatively haphazard event.

"By giving the vaccine to the donor, they can build up immunity to the cancer.

"They will have this memory, so when the transplanted bone marrow cells come into contact with myeloma they will attack it."

Past research has already shown that giving the vaccine to the patient boosts their immune system.

Dr Bishop said it was a controversial idea to vaccinate healthy donors, but that was entirely safe.

The big issue is whether it is ethically acceptable to vaccinate donors.

A spokesman from the Leukaemia Research Fund

"The protein the vaccine is based on is a byproduct of the cancer. It does not give you cancer.

"There is no risk to the donor, other than those related to any vaccine."

He said the beauty of the treatment was that it would only attack the myeloma cells and would not harm healthy cells because its target was so specific.

He said it might be possible to treat other cancers with similarly unique targets, such as some forms of lymphoma, in the same way.

"We are very pleased with initial results."

He hopes it will be available as a treatment in coming years.

A spokesman from the Leukaemia Research Fund said: "The concept is very attractive, but there are various hurdles to get over that affect both the donor and the patient.

"The big issue is whether it is ethically acceptable to vaccinate donors."

Professor Peter Johnson, of the Cancer Research UK cancer unit at Southampton General Hospital, said: "The reason we can ethically and reasonably do that is because this is a unique antigen [target] which is only present on malignant cells in the recipient marrow."






http://news.bbc.co.uk/1/hi/health/4227361.stm

Hi All
Does anybody have an idea as to where the hell this announcement has got to? I'm getting bored waiting

DB has been on holiday the last 2 weeks but is due back in the office on Tuesday...

Mitzy
Thanks for the update, lets hope he comes back with the 'best' of information.

This is begining to sound like the advfn PET board........